Synthetic Biologics, Inc. (SYN)’s Stock Price Update:
Synthetic Biologics, Inc. (SYN) stock price ended its day with loss -0.93% and finalized at the price of $0.53, its 52 week- peak value and changed 9.28% from its 52 week-bottom price value. During its last trading session, Stock traded with the total exchanged volume of 0.02 million shares. The average volume stands around 0.13 million shares. The average numbers of shares are traded in a security per day, during the recent 3-month period. The stock has relative volume of 0.15. Relative volume is ratio between current volume and 3-month average value, intraday adjusted.
Return on Assets (ROA) ratio indicates how profitable a company is relative to its total assets. The ROA is -141.50%. A company that manages their assets well will have a high return, while if manages their assets poorly will have a low return.
ATR value of company was 0.03. Average True Range (ATR) is an indicator based on trading ranges smoothed by an N-period exponential moving average percentage of the true range values. ATR can display volatility of stocks, ETFs and indexes. The principal of ATR is very similar to other volatility indicators: A high ATR value signals a possible trend change. A low ATR value correlates with a weaker trend movement.
To review the SYN previous performance, look at its past history, which highlighted below: During last 5 trades the stock sticks almost 1.92%. During last one month it showed the change of -1.96%. During last 3 month it remained at -23.19%. During last 12 month it moved at -93.12%. Along with these its year to date performance is standing at -5.36%.
In USA Industry, Synthetic Biologics, Inc. (SYN) have 17.22 million outstanding shares currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s officers and insiders. The company have shares float of 16.47 million. Float is the number of shares available for trading of a particular stock. Floating stock is calculated by subtracting closely-held shares and restricted stock from a firm’s total outstanding shares. Closely-held shares are those owned by insiders, major shareholders and employees, while restricted stock refers to insider shares that cannot be traded because of a temporary restriction such as the lock-up period after an initial public offering. A stock with a small float will generally be more volatile than a stock with a large float, apart from having limited liquidity and wider bid-ask spread. Because of these issues, institutional investors seldom invest in low-float stocks.
Analysts’ mean recommendation for Synthetic Biologics, Inc. (SYN) stands at 2.00. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.
USA based company, Synthetic Biologics, Inc. (SYN)’s latest closing price distance was -39.66% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -6.24% and 1.38% compared with the 20 Day Moving Average.
The stock price weekly volatility remained at 6.62% while volatility is standing at 6.11% for the month. Volatility refers to the amount of uncertainty or risk about the size of changes in a security’s value. A higher volatility means that a security’s value can potentially be spread out over a larger range of values. This means that the price of the security can change dramatically over a short time period in either direction. A lower volatility means that a security’s value does not fluctuate dramatically, but changes in value at a steady pace over a period of time. Commonly, the higher the volatility, the riskier the security.
Jennifer Medina- Technology
I am Jennifer Medina and I give “Nasdaqclick.com” the best and deepest insights into the latest happenings in the Innovation and technology segment. My journey started as an independent financial consultant for more than 13 years in the city and my craving to see the world has taken me to nations around the globe and given me the chance to report for a portion of the best news associations. Lately, I have started to use my envelopment and experience in healthcare financial news to become a full-time editor.
Address: 2648 Islington Ave
Toronto, ON M9V 2X5, Canada
Phone Number: +1 416 411 4123